DYN
Dyne Therapeutics, Inc.NASDAQHealthcare$18.84-2.60%ClosedMarket Cap: $3.11B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.42
P/S
0.00
EV/EBITDA
-4.92
DCF Value
$6.74
FCF Yield
-14.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-61.5%
ROA
-37.6%
ROIC
-41.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-116.1M | $-112.0M | $-0.76 | — |
| FY 2025 | $0.00 | -Infinity% | $-468.2M | $-446.2M | $-3.47 | — |
| Q3 2025 | $0.00 | NaN% | $-113.9M | $-108.0M | $-0.76 | — |
| Q2 2025 | $0.00 | NaN% | $-115.8M | $-110.9M | $-0.97 | — |
| Q1 2025 | $0.00 | NaN% | $-122.4M | $-115.4M | $-1.05 | — |
| Q4 2024 | $0.00 | NaN% | $-97.1M | $-89.5M | $-0.88 | — |
| FY 2024 | $0.00 | -Infinity% | $-343.9M | $-317.4M | $-3.37 | — |
| Q3 2024 | $0.00 | NaN% | $-105.7M | $-97.1M | $-0.96 | — |
| Q2 2024 | $0.00 | NaN% | $-72.0M | $-65.1M | $-0.70 | — |
| Q1 2024 | $0.00 | NaN% | $-69.2M | $-65.6M | $-0.81 | — |
| Q4 2023 | $0.00 | NaN% | $-67.7M | $-66.6M | $-1.09 | — |
| FY 2023 | $0.00 | -Infinity% | $-242.2M | $-235.9M | $-3.95 | — |